Scientists from the University of Southampton have been awarded £9.2m to support groundbreaking clinical trials.
The funding comes as part of a £112 million national investment.
The Researchers have previously made serious breakthroughs including developing a new screening test for diabetes, led a national trial of a new chicken pox vaccination, discovered a drug that can slow the progression of incurable and fatal lung cancer.
The funds from the Department of Health and National Institute for Health Research (NIHR) will be used to support the continued research of the NIHR Wellcome Trust Southampton Clinical Research Facility (SCRF), a partnership between the University and Southampton General Hospital.
Professor Saul Faust, Director of the NIHR Wellcome Trust SCRF said: “We are delighted to have secured this funding for the next five years as it gives us a fantastic opportunity to continue to lead developments in many areas of medicine as well as collaborate with our colleagues on major international breakthroughs.”
This follows an announcement in September of £15m awarded to the NIHR Biomedical Research Centre in Southampton to tackle obesity, asthma, allergies and infections.